---
title: "Hansen Pharmaceutical: Canagliflozin tablets complete drug registration"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/227868234.md"
description: "According to the Zhitong Finance APP, Hansen Pharmaceutical announced that the company recently received the \"Drug Registration Certificate\" for the chemical drug \"Empagliflozin Tablets\" issued by the National Medical Products Administration. This drug is indicated for the treatment of type 2 diabetes and for adult patients with symptomatic chronic heart failure to reduce the risk of hospitalization due to heart failure"
datetime: "2025-02-11T09:55:03.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/227868234.md)
  - [en](https://longbridge.com/en/news/227868234.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/227868234.md)
generator: "portal-rs"
---

# Hansen Pharmaceutical: Canagliflozin tablets complete drug registration

According to the Zhitong Finance APP, Hansen Pharmaceutical (002412.SZ) announced that the company recently received the "Drug Registration Certificate" for the chemical drug "Empagliflozin Tablets" approved by the National Medical Products Administration. This drug is indicated for the treatment of type 2 diabetes and for adult patients with symptomatic chronic heart failure to reduce the risk of hospitalization due to heart failure

### Related Stocks

- [002412.CN](https://longbridge.com/en/quote/002412.CN.md)

## Related News & Research

- [Northstar Clean Tech wins new US patent for asphalt shingle reprocessing technology](https://longbridge.com/en/news/297153537.md)
- [Harmonychain Reaches Key Milestone in Lokotech ASIC Production](https://longbridge.com/en/news/297223350.md)
- [Hermes eyes doubling revenue on thermal modules](https://longbridge.com/en/news/296937799.md)
- [AcuCort says Zeqmelit oral film wins 69% patient preference in real-world study](https://longbridge.com/en/news/296994929.md)
- [Panda Express’ CEOs are on a ‘mission’ to help workers achieve the dream of home ownership](https://longbridge.com/en/news/297055215.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**